At a glance
Novel approaches to support therapeutic development in ultra-rare cancers is a federal competitive grant from Food and Drug Administration for the science & technology sector. Eligible applicants: Independent school districts; Native American tribal organizations (other than Federally recognized tribal governments); Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Non. Applications are accepted on a rolling basis. Apply via the official listing at www.grants.gov.
- Amount
- See listing
- Deadline
- Rolling
- Type
- Competitive
- Status
- Forecasted
About this program
The purpose of this program is to support new approaches that can be applied to facilitate therapeutic development in ultra-rare pediatric and adult cancers, including molecularly-defined subsets of more common cancers. Specific areas of interest include, but are not limited to, the following examples:• Development of infrastructure for a coordination network and data repository for patient-level data across institutions and internationally to support drug development and regulatory decision-making for one or more ultra-rare cancers.• Investigations to explore opportunities to develop and validate early clinical endpoints and other novel efficacy endpoints for evaluation of treatments for ultra-rare cancers.• Development and implementation of a collaborative multi-stakeholder effort to support generation and use of real-world data leveraging a registry framework for use in development of new therapies for pediatric patients with diffuse midline glioma (DMG) (including diffuse intrinsic pontine glioma, DIPG). • Innovative approaches to identify new biologically-driven opportunities for clinical development of previously approved drugs or biologics (hereafter referred to as drugs), including drugs for which development has been discontinued, in ultra-rare cancers.• Research to develop novel approaches to preserve the availability of drugs for which commercial developers have discontinued adult development that have strong potential in ultra-rare cancers but lack financial incentives for commercial development• Development of methods to incorporate use of telemedicine and/or pragmatic trial design elements (e.g., collecting laboratory and/or imaging data from local facilities) for patient assessments to facilitate enrollment of patients with ultra-rare cancers• Development of nanoparticle-based delivery approaches for therapeutic nucleic acids targeting onco-fusion transcription factors in metastatic tumor animal models using targeted bioPROTAC degradation or genomic editing strategies. Successful efforts should demonstrate effective delivery and expression in-vivo to tumor cells, and downregulation of the target transcription factor protein while minimizing off-target effects and limiting sequestration of the nanoparticle by the liver, spleen, and lungs.• Research to exhaustively characterize the plasma-membrane protein expression (surfaceome) of an ultra-rare cancer and the presumed healthy tissue of origin, as well as the resident-tissue stem cells, by single-cell transcriptomics and proteomics. These studies, and available correlative database analyses, should be designed to identify possible combinatorial signatures of plasma membrane proteins unique to the ultra-rare tumor. Tumors of interest include Sclerosing epithelioid fibrosarcoma and atypical teratoid rhabdoid tumors (ATRT).
Who can apply
Independent school districts; Native American tribal organizations (other than Federally recognized tribal governments); Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; City or township governments; Native American tribal governments (Federally recognized); Small businesses; Private institutions of higher education; Public housing authorities/Indian housing authorities; For profit organizations other than small businesses; County governments; Public and State controlled institutions of higher education; Special district governments; State governments
How to apply
Apply through Grants.gov using funding opportunity number FOR-FD-26-004. Register your organization (SAM.gov + Grants.gov) before the deadline, then submit the application package listed in the official notice.
Apply at official sourceRelated grants
- Enhancing Mechanistic Research on Precision Probiotic Therapies (R33 Clinical Trial Optional) NIH · Up to $25K · Jun 2, 2027 Open
- Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional) NIH · See listing · Jan 7, 2028 Open
- Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Allowed) NIH · See listing · Jan 7, 2028 Open
- NHLBI Career Transition Award for Intramural Postdoctoral Fellows and Research Trainees (K22 Independent Clinical Trial Not Allowed) NIH · See listing · Jul 12, 2027 Open